» Articles » PMID: 20074042

SUMO in the Mammalian Response to DNA Damage

Overview
Specialty Biochemistry
Date 2010 Jan 16
PMID 20074042
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Modification by SUMOs (small ubiquitin-related modifiers) is largely transient and considered to alter protein function through altered protein-protein interactions. These modifications are significant regulators of the response to DNA damage in eukaryotic model organisms and SUMOylation affects a large number of proteins in mammalian cells, including several proteins involved in the response to genomic lesions [Golebiowski, Matic, Tatham, Cole, Yin, Nakamura, Cox, Barton, Mann and Hay (2009) Sci. Signaling 2, ra24]. Furthermore, recent work [Morris, Boutell, Keppler, Densham, Weekes, Alamshah, Butler, Galanty, Pangon, Kiuchi, Ng and Solomon (2009) Nature 462, 886-890; Galanty, Belotserkovskaya, Coates, Polo, Miller and Jackson (2009) Nature 462, 935-939] has revealed the involvement of the SUMO cascade in the BRCA1 (breast-cancer susceptibility gene 1) pathway response after DNA damage. The present review examines roles described for the SUMO pathway in the way mammalian cells respond to genotoxic stress.

Citing Articles

Deciphering the role of post-translational modifications in fanconi anemia proteins and their influence on tumorigenesis.

Ma R, Xu X Cancer Gene Ther. 2024; 31(8):1113-1123.

PMID: 38879655 DOI: 10.1038/s41417-024-00797-1.


Repression of the SUMO-conjugating enzyme UBC9 is associated with lowered double minutes and reduced tumor progression.

Wang Y, Zou H, Ji W, Huang M, You B, Sun N Cancer Biol Ther. 2024; 25(1):2323768.

PMID: 38465861 PMC: 10936631. DOI: 10.1080/15384047.2024.2323768.


Ubiquitin Proteasome Gene Signatures in Ependymoma Molecular Subtypes.

Vriend J, Thanasupawat T, Sinha N, Klonisch T Int J Mol Sci. 2022; 23(20).

PMID: 36293188 PMC: 9604155. DOI: 10.3390/ijms232012330.


Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics.

Krishna A, John S, Shinde P, Mishra R Cancer Cell Int. 2021; 21(1):575.

PMID: 34715855 PMC: 8555349. DOI: 10.1186/s12935-021-02279-y.


Adenovirus E4-ORF3 Targets PIAS3 and Together with E1B-55K Remodels SUMO Interactions in the Nucleus and at Virus Genome Replication Domains.

Higginbotham J, OShea C J Virol. 2015; 89(20):10260-72.

PMID: 26223632 PMC: 4580165. DOI: 10.1128/JVI.01091-15.